Noxon flexes its muscles

The multi-million euro funding round is led by High-Tech Gründerfonds (HTGF) and Bayern Kapital. Auxxo and another institutional investor are also participating. The company has not disclosed the exact amount of the financing.

The Munich-based startup plans to use the new capital to advance its certification as a Class IIa medical device and bring its first therapy modules to market. The goal is to make muscle health transparent, personalized, and affordable for everyone.

Platform for muscle diagnostics and stimulation

According to Noxon, the technology combines continuous muscle diagnostics with neuromuscular electrical stimulation in a wearable device suitable for everyday use for the first time. The goal is a closed feedback loop of real-time measurement and personalized muscle and nerve activation throughout the entire course of therapy. The company states that pilot studies are currently underway and a further clinical trial is planned.

In rehabilitation and for neuromuscular diseases, diagnostics and muscle activation are currently mostly performed sporadically under clinical conditions. This results in a lack of continuous data from everyday life. Noxon aims to remedy this. According to the company, its textile-based sensor and stimulation elements can be integrated into existing products such as tapes, patches, or orthopedic aids.

This could not only treat tremors in Parkinson's patients, but also restore motor functions after paralysis and conduct performance analyses in elite sports.

Maria Neugschwender, CEO of Noxon, says: 

"Neurological and musculoskeletal diseases are increasing worldwide. Healthy muscle function is fundamental, but remains a blind spot for many." 

Neugschwender said that the support from investors makes it possible to further clinically validate the platform and bring the first products to market.

Pilot projects with clinical partners

In parallel, Noxon is working with medical partners on pilot applications. These include the University Hospital of Würzburg and the neuroscience group N-Squared Lab. The focus is on applications where signal transmission between the brain and muscles is impaired. These include, among other things, solutions for reducing Parkinson's tremor.

Investors also see potential in the platform. Dr. Lena-Sophie Schütter, Investment Manager at HTGF, says: 

"What convinces me about Noxon is that effective therapy becomes as easy as putting on a bandage." 

According to the company, it addresses Noxon With its modular platform, it targets a market of more than 1.1 billion people worldwide with muscle-related diseases. With the support of early-stage investors from the Bavarian ecosystem, the Munich-based startup is now working on the next stage of development. If clinical validation is successful, it could... Noxon to transfer his technology from Munich to other fields of application.